JP2002541085A - 歯内治療用繊維およびその使用方法 - Google Patents
歯内治療用繊維およびその使用方法Info
- Publication number
- JP2002541085A JP2002541085A JP2000609033A JP2000609033A JP2002541085A JP 2002541085 A JP2002541085 A JP 2002541085A JP 2000609033 A JP2000609033 A JP 2000609033A JP 2000609033 A JP2000609033 A JP 2000609033A JP 2002541085 A JP2002541085 A JP 2002541085A
- Authority
- JP
- Japan
- Prior art keywords
- endodontic
- fibers
- fiber
- treatment
- treatment site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 162
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 54
- 229940079593 drug Drugs 0.000 claims abstract description 46
- 238000013268 sustained release Methods 0.000 claims abstract description 9
- 239000012730 sustained-release form Substances 0.000 claims abstract description 9
- 229960002227 clindamycin Drugs 0.000 claims description 51
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 51
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 49
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 49
- 210000004262 dental pulp cavity Anatomy 0.000 claims description 39
- 230000003239 periodontal effect Effects 0.000 claims description 32
- 239000003242 anti bacterial agent Substances 0.000 claims description 26
- 229940088710 antibiotic agent Drugs 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- 210000004053 periapical tissue Anatomy 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012276 Endovascular treatment Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 12
- 238000002716 delivery method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000006161 blood agar Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 210000003464 cuspid Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000007910 systemic administration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 206010066901 Treatment failure Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241000605894 Porphyromonas Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- -1 techniques Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 235000015927 pasta Nutrition 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241001384595 Paratachys micros Species 0.000 description 2
- 240000000968 Parkia biglobosa Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000364021 Tulsa Species 0.000 description 2
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002568 pbsc Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000049183 Aloe parvula Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000190888 Capnocytophaga gingivalis Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001576541 Corydalis cava Species 0.000 description 1
- 241001657508 Eggerthella lenta Species 0.000 description 1
- 241001536365 Entamoeba gingivalis Species 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 244000059221 Medinilla intermedia Species 0.000 description 1
- 241000547746 Medora Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001135715 Neonauclea media Species 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 241000206591 Peptococcus Species 0.000 description 1
- 241000254101 Popillia japonica Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241001135217 Prevotella buccae Species 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000002599 Smear Layer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 241000429617 Trechoblemus micros Species 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940041669 mercury Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 229920005690 natural copolymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Dental Preparations (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12749799P | 1999-04-02 | 1999-04-02 | |
| US60/127,497 | 1999-04-02 | ||
| PCT/US2000/008582 WO2000059469A2 (en) | 1999-04-02 | 2000-03-30 | Endodontic fibers and methods of use therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541085A true JP2002541085A (ja) | 2002-12-03 |
| JP2002541085A5 JP2002541085A5 (enExample) | 2007-05-10 |
Family
ID=22430454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609033A Pending JP2002541085A (ja) | 1999-04-02 | 2000-03-30 | 歯内治療用繊維およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1165057B1 (enExample) |
| JP (1) | JP2002541085A (enExample) |
| AT (1) | ATE399540T1 (enExample) |
| CA (1) | CA2370784C (enExample) |
| CY (1) | CY1108364T1 (enExample) |
| DE (1) | DE60039351D1 (enExample) |
| DK (1) | DK1165057T3 (enExample) |
| ES (1) | ES2308975T3 (enExample) |
| PT (1) | PT1165057E (enExample) |
| WO (1) | WO2000059469A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007183281A (ja) * | 2007-01-15 | 2007-07-19 | Microdent:Kk | 健康計測診査装置、方法 |
| WO2017115906A1 (ko) * | 2015-12-31 | 2017-07-06 | 주식회사 웰나노스 | 치과용 약물 방출 생분해성 섬유 칩 및 그 제조방법 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068940A2 (en) * | 2008-12-12 | 2010-06-17 | Novalar Pharmaceuticals, Inc. | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy |
| WO2019139877A1 (en) * | 2018-01-10 | 2019-07-18 | The University Of North Carolina At Chapel Hill | Tigecycline for topical treatment of root canal space |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6099245A (ja) * | 1983-10-07 | 1985-06-03 | ザ フオーサイス デンタル インフアーマリー フオアチルドレン デイ．ビイ．エイ．フオーサイス デンタル センター | 治療薬供給装置 |
| JPS63303922A (ja) * | 1987-06-02 | 1988-12-12 | Rooto Seiyaku Kk | 根管治療剤 |
| JPH11349425A (ja) * | 1998-03-27 | 1999-12-21 | Roeko Gmbh & Co Dentalerzeugnisse | 根管充填用の抗菌的に有効な材料とその製法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764377A (en) | 1983-10-07 | 1988-08-16 | The Forsyth Dental Infirmary For Children | Intra-pocket drug delivery devices for treatment of periodontal diseases |
| US4892736A (en) | 1983-10-07 | 1990-01-09 | The Forsyth Dental Infirmary For Children | Intra-pocket drug delivery devices for treatment of periodontal diseases |
| US5114718A (en) * | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
-
2000
- 2000-03-30 PT PT00919955T patent/PT1165057E/pt unknown
- 2000-03-30 AT AT00919955T patent/ATE399540T1/de active
- 2000-03-30 JP JP2000609033A patent/JP2002541085A/ja active Pending
- 2000-03-30 DK DK00919955T patent/DK1165057T3/da active
- 2000-03-30 EP EP00919955A patent/EP1165057B1/en not_active Expired - Lifetime
- 2000-03-30 CA CA2370784A patent/CA2370784C/en not_active Expired - Fee Related
- 2000-03-30 ES ES00919955T patent/ES2308975T3/es not_active Expired - Lifetime
- 2000-03-30 EP EP08011836A patent/EP1985291A3/en not_active Withdrawn
- 2000-03-30 DE DE60039351T patent/DE60039351D1/de not_active Expired - Lifetime
- 2000-03-30 WO PCT/US2000/008582 patent/WO2000059469A2/en not_active Ceased
-
2008
- 2008-09-24 CY CY20081101034T patent/CY1108364T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6099245A (ja) * | 1983-10-07 | 1985-06-03 | ザ フオーサイス デンタル インフアーマリー フオアチルドレン デイ．ビイ．エイ．フオーサイス デンタル センター | 治療薬供給装置 |
| JPS63303922A (ja) * | 1987-06-02 | 1988-12-12 | Rooto Seiyaku Kk | 根管治療剤 |
| JPH11349425A (ja) * | 1998-03-27 | 1999-12-21 | Roeko Gmbh & Co Dentalerzeugnisse | 根管充填用の抗菌的に有効な材料とその製法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007183281A (ja) * | 2007-01-15 | 2007-07-19 | Microdent:Kk | 健康計測診査装置、方法 |
| WO2017115906A1 (ko) * | 2015-12-31 | 2017-07-06 | 주식회사 웰나노스 | 치과용 약물 방출 생분해성 섬유 칩 및 그 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1165057A2 (en) | 2002-01-02 |
| CY1108364T1 (el) | 2014-02-12 |
| CA2370784A1 (en) | 2000-10-12 |
| WO2000059469A3 (en) | 2001-03-15 |
| DE60039351D1 (de) | 2008-08-14 |
| CA2370784C (en) | 2010-10-05 |
| EP1985291A3 (en) | 2012-02-15 |
| WO2000059469A2 (en) | 2000-10-12 |
| PT1165057E (pt) | 2008-09-04 |
| WO2000059469A9 (en) | 2002-02-14 |
| ES2308975T3 (es) | 2008-12-16 |
| EP1985291A2 (en) | 2008-10-29 |
| DK1165057T3 (da) | 2008-11-10 |
| EP1165057B1 (en) | 2008-07-02 |
| ATE399540T1 (de) | 2008-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7946849B2 (en) | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy | |
| Renvert et al. | Mechanical and repeated antimicrobial therapy using a local drug delivery system in the treatment of peri‐implantitis: a randomized clinical trial | |
| Ng et al. | Endodontic photodynamic therapy ex vivo | |
| Akıncıbay et al. | Application of chitosan gel in the treatment of chronic periodontitis | |
| Ritter et al. | Pulp revascularization of replanted immature dog teeth after treatment with minocycline and doxycycline assessed by laser Doppler flowmetry, radiography, and histology | |
| Gilad et al. | Development of a clindamycin-impregnated fiber as an intracanal medication in endodontic therapy | |
| Souza et al. | Antimicrobial activity of hypochlorite solutions and reciprocating instrumentation associated with photodynamic therapy on root canals infected with Enterococcus faecalis–An in vitro study | |
| Afkhami et al. | Residual antibacterial effects of a mixture of silver nanoparticles/calcium hydroxide and other root canal medicaments against Enterococcus faecalis | |
| Ramesh et al. | Local Drug Delivery in periodontal diseases.…… A Review | |
| Panwar et al. | Local drug delivery with tetracycline fiber: An alternative to surgical periodontal therapy | |
| Hartley et al. | Use of antibiotic impregnated polymethylmethacrylate beads for the treatment of chronic mandibular osteomyelitis in a Bennett's wallaby (Macropus rufo‐griseus rufogriseus) | |
| JP2002541085A (ja) | 歯内治療用繊維およびその使用方法 | |
| Jain et al. | Comparative Evaluation of Antimicrobial Efficacy of Calcium Hydroxide, Triple Antibiotic Paste, and 2% Chlorhexidine Combined with 0.5% Cetrimide against Enterococcus faecalis Biofilm-Infected Dentin Model: An: In vitro: Study | |
| US20120021384A1 (en) | Characterization of an antibiotic imregnated delivery systems as an intracanal medicament in endodontic therapy | |
| Al-Sabawi et al. | Residual antibacterial effect of calcium hydroxide combined with chlorhexidine gel as an intracanal medicament | |
| Metzger et al. | Immediate root canal disinfection with ultraviolet light: an ex vivo feasibility study | |
| Saini et al. | Comparative clinical evaluation of two local drug delivery agents (neem chip and turmeric chip) in chronic periodontitis: an experimental study | |
| Gupta et al. | Effectiveness of Controlled Release Chlorhexidine Chip as an Adjunctive to Scaling and Root Planning for the Treatment of Chronic Periodontitis. | |
| Abinaya | Comparative Evaluation of Antimicrobial Efficacy of Bioactive Glass, 1% Chlorhexidine Gluconate with Calcium Hydroxide and 1% Chlorhexidine Gluconate, as Intracanal Medicament in Primary Molars | |
| CA2343471C (en) | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy | |
| RU2258546C1 (ru) | Способ подавления патогенной микрофлоры | |
| Karameh et al. | A Systematic Review of Antibiotic Use in Dental Implant Therapy: Efficacy, Guidelines, and Recommendations | |
| Teimoory et al. | Antibacterial behavior of silver diamine fluoride, sodium hypochlorite and ozone Gel on Enterococcus faecalis in root canal of deciduous teeth | |
| Saeed et al. | Comparative evaluation and efficacy of linezolid, vancomycin and ciprofloxacin on enterococcal induced biofilm using scanning electron microscopy an in vitro study | |
| WO2025099450A1 (en) | Dental paste |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100716 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101014 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101116 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110330 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110603 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110726 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120528 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121022 |